Good news bad news on the Chris Sale injury front.
The good; at this time the Red Sox left-hander does not need Tommy John surgery.
The bad; he still might down the road.
The Athletic’s Ken Rosenthal was first to report the Sale news.
Interim manager Ron Roenicke told reporters earlier Wednesday that the team was still waiting to hear from renowned surgeon Dr. Neal ElAttrache. Prior to ElAttrache Sale was examined by surgeon Dr. James Andrews.
“We want as many opinions as we can,” Roenicke told reporters in Fort Myers. “Dr. Andrews saw it and read the MRI. I don’t want to comment on it until we get one more opinion.”
Sale’s elbow soreness was first reported on Tuesday a couple days after Sale threw a live BP session.
Chris Sale felt elbow soreness yesterday after live BP. They sent him for an MRI. Results not back yet.
— Chris Cotillo (@ChrisCotillo) March 3, 2020
Sale was shut down last August after dealing with elbow inflammation. During that time, he received a platelet-rich plasma treatment after he made a visit to Dr. James Andrews. At the time it was understood that there was no damage, but instead just inflammation. The belief was that Sale would be able to partake fully during the 2020 spring, but following his late start after a battle with pneumonia, things seem to be taking a turn for the worst.
Prior to the start of the 2019 season, Sale and the Red Sox came to an agreement on what would be a five year extension worth $145 million. This is the first year of that new deal.